Atsushi Osada is Head of Materia Japan and Vice President of Clinical Development. Prior to joining Materia Therapeutics, Atsushi earned a Duke MBA while accruing more than 20 years of experience leading oncology development programs, global clinical operations, and strategic healthcare initiatives. He has held leadership roles at Boehringer Ingelheim, NanoCarrier Co., Ltd., Eli Lilly, and Oji Holdings Corporation. He built expertise in translational oncology development, cross-border program execution, and international stakeholder management. At NanoCarrier, Mr. Osada directed multiple international oncology clinical trials across more than 40 cancer hospitals in over 15 countries. His experience includes GCP-compliant clinical execution, oncology program strategy, scientific publication coordination, and operational leadership resulting in FDA Fast Track designation. Currently, he leads the lead oncology program, MATH-01, where he oversees CMC, nonclinical, translational, and external partner activities globally.